Matthew W. Foehr - Nov 1, 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Former Executive Officer
Signature
/s/ Charles Berkman, Attorney-in-Fact
Stock symbol
LGND
Transactions as of
Nov 1, 2022
Transactions value $
$0
Form type
4
Date filed
11/3/2022, 09:06 PM
Previous filing
Sep 30, 2022
Next filing
Nov 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Disposed to Issuer -20.3K -11.13% 162K Nov 1, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Employee Stock Option (right to buy) Disposed to Issuer -34.2K -100% 0 Nov 1, 2022 Common Stock 34.2K $90.68 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Matthew W. Foehr is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022.
F2 The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.